& Singh, P
Carroll, MD, co-founder and chief medical director of GLPrelief, and founder of BeSlimMD in Maitland, FL, who said that many times the what makes people stop taking GLP-1 drugs once they start is not the needle its how the medication makes them feel, and what it costs
People who cease taking GLP-1 obesity drugs, which include semaglutide (Wegovy) and tirzepatide (Zepbound), typically regain an average of nearly a pound a month, ultimately gaining back all the weight they lost within two years, according to a review of 37 earlier studies
Unlike approved pharmaceutical products, this formulation is intended exclusively for qualified researchers conducting controlled in vitro studies
Constipation due to decreased gastric motility is one of the most experienced side effects of GLP-1 drugs
The most frequent injuries involve long-term digestive problems, inflammation of the pancreas, gallbladder disease, kidney injury, and growing concerns about thyroid tumors